NOXXON Pharma N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALNOX.PA research report →
About the company
NOXXON Pharma N. V. , a biopharmaceutical enterprise founded in 1997 and based in Berlin, Germany, is currently in the clinical phase of developing its unique cancer treatments.
- CEO
- Aram Mangasarian
- IPO
- 2018
- Employees
- 13
- HQ
- Berlin, DE
- Market Cap
- $0
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.54
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -236.45%
- ROIC
- -186.50%
- Revenue
- $0 · 0.00%
- Net Income
- $-14,453,000 · 6.52%
- EPS
- $-45.99 · 3.75%
- Op Income
- $-12,947,000
- FCF YoY
- -135.51%
- 52W High
- $0.41
- 52W Low
- $0.04
- 50D MA
- $0.07
- 200D MA
- $0.18
- Beta
- 2.24
- Avg Volume
- 4.35M
Get TickerSpark's AI analysis on ALNOX.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALNOX.PA coverage
Recent articles, reports, and earnings notes.
No research on ALNOX.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALNOX.PA report →Similar companies
Peers in the same neighborhood.